Contact

Prof. Dr. Jörg Steinbach
Executive Director (alternating)
Institute of Radiopharmaceutical Cancer Research
j.steinbachAthzdr.de
Phone: +49 351 260 - 3170, 3223
Fax: +49 351 260 - 13170

Prof. Dr. Michael Bachmann
Executive Director (alternating)
Radioimmunology
m.bachmannAthzdr.de
Phone: +49 351 260 - 3170, +49 172 694 8424
Fax: +49 351 260 - 3232

Marita Kersten
Secretariat / Administration
Institute of Radiopharmaceutical Cancer Research
m.kerstenAthzdr.de
Phone: +49 351 260 - 3223
Fax: 13223, 3232

Partners

Vorschau-Bild
Vorschau-Bild
Vorschau-Bild
Vorschau-Bild
Vorschau-Bild

Departments of Radiopharmaceutical Cancer Research

Radionuclide Theragnostics, Dr. Hans-Jürgen PietzschDepartment of Radionuclide Theragnostics


Radiopharmaceutical and Chemical Biology, Prof. Dr. Jens PietzschDepartment of Radiopharmaceutical and Chemical Biology

  • Organic and Radiochemistry
  • Tumor-specific PET Radiotracers
  • Radiopharmacology and Imaging
  • Molecular Mechanisms in Solid Tumors
  • Biomaterials and Imaging

Positron Emission Tomography, Prof. Dr. Jörg van den HoffDepartment of Positron Emission Tomography

  • Improved quantification of functional information in oncological PET
  • Quantitative perfusion imaging using functional ASL-MRI
  • Multimodal imaging and assessment of in-vivo quantification accuracy
  • Motion compensation methods for PET
  • High resolution PET image reconstruction

Neuroradiopharmaceuticals, Prof. Dr. Peter Brust, Dr. Winnie Deuther-ConradDepartment of Neuroradiopharmaceuticals

  • Molecular imaging of adenosine signalling in cancer
  • Molecular imaging of α7 nAChR in cancer and brain diseases
  • [18F]Flubatine - a potential PET marker of early Alzheimer`s disease
  • Development of new ligands and 18F-radiotracers for the vesicular acetylcholine transporter (VAChT) in brain
  • New PET Radioligands for Imaging of Cannabinoid Receptors Type 2 (CB2) in the Human Brain
  • Radioligands for PET Imaging of Cyclic Nucleotide Phosphodiesterases 2A, 5A and 10A
  • Development of 18F-labelled PET radiotracers for the imaging of σ receptors in cancer and brain diseases

Radioimmunology, Prof. Dr. Michael BachmannDepartment of Radioimmunology

  • Antibody-based immunotherapeutics and diagnostics for therapy and imaging of tumors
  • Cellular immunotherapeutics for an individualized immunotherapy and diagnostics
  • Modulation of the tumor microenvironment via manipulation with regulatory T cells and checkpoint inhibitors
  • Combination of immunotherapies with other tumor therapies (e.g. external or internal radiotherapy)

Radiopharmaceuticals Production, Dr. Frank FüchtnerDepartment of Radiopharmaceuticals Production

  • GMP-certified Radiopharmaceuticals Production
  • Radiotracer and Radionuclides for Science

Contact

Prof. Dr. Jörg Steinbach
Executive Director (alternating)
Institute of Radiopharmaceutical Cancer Research
j.steinbachAthzdr.de
Phone: +49 351 260 - 3170, 3223
Fax: +49 351 260 - 13170

Prof. Dr. Michael Bachmann
Executive Director (alternating)
Radioimmunology
m.bachmannAthzdr.de
Phone: +49 351 260 - 3170, +49 172 694 8424
Fax: +49 351 260 - 3232

Marita Kersten
Secretariat / Administration
Institute of Radiopharmaceutical Cancer Research
m.kerstenAthzdr.de
Phone: +49 351 260 - 3223
Fax: 13223, 3232